MX2020001547A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Info

Publication number
MX2020001547A
MX2020001547A MX2020001547A MX2020001547A MX2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A
Authority
MX
Mexico
Prior art keywords
fluorobenzofuran
indol
dione
methyl
solid forms
Prior art date
Application number
MX2020001547A
Other languages
English (en)
Spanish (es)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001547(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2020001547A publication Critical patent/MX2020001547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
MX2020001547A 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. MX2020001547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
MX2020001547A true MX2020001547A (es) 2020-08-03

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020001547A MX2020001547A (es) 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2024003249A MX2024003249A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2024003249A MX2024003249A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Country Status (16)

Country Link
US (3) US11136334B2 (https=)
EP (1) EP3665176B1 (https=)
JP (3) JP7424639B2 (https=)
KR (3) KR102700883B1 (https=)
CN (2) CN117362305A (https=)
AU (3) AU2018313259B2 (https=)
BR (1) BR112020002892A2 (https=)
CA (1) CA3072240A1 (https=)
DK (1) DK3665176T3 (https=)
ES (1) ES2974328T3 (https=)
FI (1) FI3665176T3 (https=)
IL (2) IL272556B2 (https=)
MX (3) MX2020001547A (https=)
PL (1) PL3665176T3 (https=)
PT (1) PT3665176T (https=)
WO (1) WO2019032958A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697794T3 (pl) 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
PH12012501293A1 (en) 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
CN117362305A (zh) 2024-01-09
ES2974328T3 (es) 2024-06-26
PL3665176T3 (pl) 2024-06-17
JP7778750B2 (ja) 2025-12-02
IL313800A (en) 2024-08-01
BR112020002892A2 (pt) 2020-08-04
KR102700883B1 (ko) 2024-09-02
JP2023156372A (ja) 2023-10-24
KR20240063198A (ko) 2024-05-09
KR20250070131A (ko) 2025-05-20
AU2025202936A1 (en) 2025-05-15
CN111247153B (zh) 2024-04-02
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
IL272556B1 (en) 2024-09-01
AU2023201059A1 (en) 2023-03-23
EP3665176A1 (en) 2020-06-17
DK3665176T3 (da) 2024-03-25
JP2020530497A (ja) 2020-10-22
US20250115616A1 (en) 2025-04-10
US20200223861A1 (en) 2020-07-16
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
AU2018313259B2 (en) 2022-11-24
CA3072240A1 (en) 2019-02-14
AU2023201059B2 (en) 2025-04-03
PT3665176T (pt) 2024-03-13
AU2018313259A1 (en) 2020-02-27
EP3665176B1 (en) 2024-01-24
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
IL272556A (en) 2020-03-31
MX2023005875A (es) 2023-06-05
CN111247153A (zh) 2020-06-05
JP7424639B2 (ja) 2024-01-30
JP2026012715A (ja) 2026-01-27
IL272556B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EP4574832A3 (en) Dantrolene prodrugs and methods of their use
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
EP3586836A4 (en) PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT AND TREAT PANCREE CANCER, CONTAINING GOSSYPOL AND PHENFORMIN AS ACTIVE INGREDIENTS
ZA202002740B (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
UY30046A1 (es) Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2020004105A (es) Formulacion farmaceutica.